EFFICACY OF COMBINED MODALITY TREATMENT INCLUDING NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH ESOPHAGEAL CANCER
Abstract
Short-and long-term results of combined modality treatment including neoadjuvant chemotherapy were analyzed in patients with stage II-III esophageal cancer. Group I patients (n=18) received 2 courses of combined gemzar/cisplatin chemotherapy followed by radical surgery. The control group patients (n=20) underwent surgery alone. In the adjuvant chemotherapy group, the rate of immediate response was 38.9 % and complete response was observed in 1 (5.6 %) patient. Treatment was well tolerated by patients. The rates of postoperative complications did not significantly differ between the groups (22.2 % and 25.0 %, respectively, p>0.05). Combined modality treatment including neoadjuvant chemotherapy provided better 2-year overall and relapse-free survival rates than surgery alone (87.5 ± 8.2 % and 87.5 ± 8.2 % compared to 63.2 ± 11.1 % and 47.4 ± 11.4 %, respectively, р<0.05).
About the Authors
Yu. V. Rudyk
Cancer Research Institute, Siberian Branch of the Russian Academy of Medical Sciences, Tomsk
Russian Federation
Russian Federation
S. G. Afanasyev
Cancer Research Institute, Siberian Branch of the Russian Academy of Medical Sciences, Tomsk
Russian Federation
Russian Federation
S. A. Tuzikov
Cancer Research Institute, Siberian Branch of the Russian Academy of Medical Sciences, Tomsk, Siberian State Medical University, Tomsk2
Russian Federation
Russian Federation
A. Yu. Dobrodeev
Cancer Research Institute, Siberian Branch of the Russian Academy of Medical Sciences, Tomsk
Russian Federation
Russian Federation
E. N. Samtsov
Cancer Research Institute, Siberian Branch of the Russian Academy of Medical Sciences, Tomsk
Russian Federation
Russian Federation
I. G. Frolova
Cancer Research Institute, Siberian Branch of the Russian Academy of Medical Sciences, Tomsk
Russian Federation
Russian Federation
I. G. Savelyev
Cancer Research Institute, Siberian Branch of the Russian Academy of Medical Sciences, Tomsk
Russian Federation
Russian Federation
References
1. Волкова Е.Э., Вашакмадзе Л.А., Хомяков В.М., Мамонтов А.С. Ускоренная госпитальная реабилитация больных после расширенно-комбинированных операций по поводу рака грудного отдела пищевода и кардии // Сибирский онкологический журнал. 2013. № 1 (55). С. 52–58.
2. Давыдов М.И., Стилиди И.С., Бохян В.Ю. и др. Промежуточные результаты применения предоперационной химиотерапии и расширенной субтотальной резекции пищевода при раке // Анналы хирургии. 2005. № 3. С. 27–32.
3. Деньгина Н.В. Современные терапевтические возможности при раке пищевода // Практическая онкология. 2012. Т. 13, № 4. С. 276–288.
4. Состояние онкологической помощи населению России в 2012 году / Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2013. 232 с.
5. Статистика злокачественных новообразований в России и странах СНГ в 2010 г. / Под ред. М.И. Давыдова, Е.М.Аксель. М., 2012. 308 с.
6. Стилиди И.С., Бохян В.Ю., Тер-Ованесов М.Д. Результаты и перспективы хирургического лечения больных раком грудного отдела пищевода // Практическая онкология. 2003. Т. 4, № 2. С. 70–75.
7. Тюляндин С.А. Рациональная тактика лечения операбельного рака пищевода // Материалы Х Российской онкологической конференции. М., 2006. С. 85–87.
8. Scheer R.V., Fakiris A.J., Johnstone P.A. Quantifying the benefit of a pathologic complete response after neoadjuvant chemoradiotherapy in the treatment of esophageal cancer // Int. J. Radiat. Oncol. Biol. Phys. 2011. 2001. Vol. 80 (4). P. 996–1001.
9. Kelsen D.P., Ginsberg R., Pajak T.F. et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer // N. Engl. J. Med. 1998. Vol. 339. P.1979–1980.
10. Liu A.N., Huang J., Cai R.G. et al. Responses of advanced esophageal cancer to chemotherapy and prognostic factors: a report of 138 cases // Ai Zheng. 2008. Vol. 27 (4). P. 400–406.
11. Malthaner R., Fenlon D. Preoperative chemotherapy for respectable thoracic esophageal cancer (Cochrane Review) // Cochrane Database Syst Rev. 2006. Vol. 3. CD. 001556.
12. Millar J., Scullin P., Morrison A. et al. Phase II study of gemcitabine and cisplatin in locally advanced/metastatic oesophageal cancer // Br. J. Cancer. 2005. Vol. 93 (10). P. 1112–1116.
13. Wang M., Gu J., Wang H.X. et al. Retrospective study of gemcitabine based chemotherapy for unresectable or recurrent esophagus squamous cell carcinoma refractory to first line chemotherapy // Asian Pac. J. Cancer Prev. 2012. Vol. 13 (8). P. 4153–4156.
Review
For citations:
Rudyk Yu.V., Afanasyev S.G., Tuzikov S.A., Dobrodeev A.Yu., Samtsov E.N., Frolova I.G., Savelyev I.G. EFFICACY OF COMBINED MODALITY TREATMENT INCLUDING NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH ESOPHAGEAL CANCER. Siberian journal of oncology. 2013;(4):17-22. (In Russ.)
Views:
581
Email this article 
